

# Vania T M Hungria

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4467507/publications.pdf>

Version: 2024-02-01

24  
papers

3,420  
citations

566801

15  
h-index

610482

24  
g-index

24  
all docs

24  
docs citations

24  
times ranked

3774  
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	13.9	1,246
2	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , 2016, 17, 27-38.	5.1	723
3	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	13.9	268
4	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1630-1642.	5.1	237
5	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	1.7	225
6	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	0.6	146
7	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , 2021, 22, e105-e118.	5.1	136
8	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 509-518.	0.2	91
9	Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria. <i>Radiographics</i> , 2019, 39, 1077-1097.	1.4	75
10	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2021, 137, 1154-1165.	0.6	49
11	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	0.6	43
12	Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. <i>Haematologica</i> , 2008, 93, 791-792.	1.7	34
13	Observational study of multiple myeloma in Latin America. <i>Annals of Hematology</i> , 2017, 96, 65-72.	0.8	29
14	Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 155-155.	0.6	21
15	Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. <i>Health Science Reports</i> , 2019, 2, e104.	0.6	16
16	Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 84-84.	0.6	16
17	Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. <i>European Journal of Haematology</i> , 2018, 101, 556-565.	1.1	15
18	Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committee. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 200-205.	0.1	10

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. <i>British Journal of Haematology</i> , 2021, 193, 561-569.	1.2	10
20	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , 2019, 98, 941-949.	0.8	9
21	How I treat <scptriple&class</scptriple> refractory multiple myeloma. <i>British Journal of Haematology</i> , 2022, 198, 244-256.	1.2	9
22	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. <i>Annals of Hematology</i> , 2017, 96, 1693-1698.	0.8	7
23	Health-related quality of life in patients with <scplight chain</scplight chain> amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone&A&daratumumab: Results from the <scpANDROMEDA</scp> study. <i>American Journal of Hematology</i> , 2022, 97, 719-730.	2.0	3
24	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis. <i>Advances in Therapy</i> , 2020, 37, 4996-5009.	1.3	2